Aligos Therapeutics, Inc.
ALGS
$10.01
$0.141.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -55.88% | -60.16% | -76.29% | -74.60% | -63.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -55.88% | -60.16% | -76.29% | -74.60% | -63.40% |
| Cost of Revenue | -10.52% | -18.93% | -4.02% | -3.79% | 9.46% |
| Gross Profit | 6.67% | 14.07% | -13.32% | -15.33% | -31.78% |
| SG&A Expenses | -10.40% | -19.01% | -24.37% | -23.63% | -25.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.50% | -18.95% | -9.77% | -9.55% | -1.32% |
| Operating Income | 7.60% | 15.41% | -0.96% | -2.00% | -10.67% |
| Income Before Tax | -12.35% | 2.23% | 46.45% | -50.64% | 5.10% |
| Income Tax Expenses | 13.50% | 63.21% | -55.13% | -58.36% | -68.65% |
| Earnings from Continuing Operations | -12.36% | 2.05% | 46.52% | -49.65% | 5.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.36% | 2.05% | 46.52% | -49.65% | 5.78% |
| EBIT | 7.60% | 15.41% | -0.96% | -2.00% | -10.67% |
| EBITDA | 7.41% | 15.29% | -1.51% | -2.66% | -11.50% |
| EPS Basic | 6.14% | 39.18% | 68.40% | 47.85% | 71.84% |
| Normalized Basic EPS | 5.06% | 38.83% | 67.98% | 47.17% | 71.93% |
| EPS Diluted | -48.07% | 4.14% | 46.02% | 47.85% | 71.84% |
| Normalized Diluted EPS | 3.72% | 37.96% | 67.42% | 47.17% | 71.93% |
| Average Basic Shares Outstanding | 48.50% | 62.14% | 84.13% | 144.38% | 245.67% |
| Average Diluted Shares Outstanding | 49.72% | 63.63% | 86.22% | 144.46% | 245.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |